350 related articles for article (PubMed ID: 35538543)
1. Identification of ISG15 and ZFP36 as novel hypoxia- and immune-related gene signatures contributing to a new perspective for the treatment of prostate cancer by bioinformatics and experimental verification.
Lyu F; Li Y; Yan Z; He Q; Cheng L; Zhang P; Liu B; Liu C; Song Y; Xing Y
J Transl Med; 2022 May; 20(1):202. PubMed ID: 35538543
[TBL] [Abstract][Full Text] [Related]
2. A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer.
Yang X; Weng X; Yang Y; Zhang M; Xiu Y; Peng W; Liao X; Xu M; Sun Y; Liu X
Aging (Albany NY); 2021 Aug; 13(15):19486-19509. PubMed ID: 34341184
[TBL] [Abstract][Full Text] [Related]
3. A bioinformatics analysis and an experimental validation of the hypoxia-related prognostic model.
Zhou L; Zhang W; Ni H; Liu J; Sun H; Liang Z; Wang R; Xue X; Chen K; Li W
J Gastrointest Oncol; 2023 Jun; 14(3):1504-1524. PubMed ID: 37435230
[TBL] [Abstract][Full Text] [Related]
4. ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress.
Yuan D; Fang Y; Chen W; Jiang K; Zhu G; Wang W; Zhang W; You G; Jia Z; Zhu J
Oxid Med Cell Longev; 2022; 2022():3611540. PubMed ID: 36111167
[TBL] [Abstract][Full Text] [Related]
5. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
6. Identification and validation of a novel overall survival prediction model for immune-related genes in bone metastases of prostate cancer.
Bi W; Guo W; Fan G; Xie L; Jiang C
Aging (Albany NY); 2023 Jul; 15(14):7161-7186. PubMed ID: 37494663
[TBL] [Abstract][Full Text] [Related]
7. Classification of pyroptosis patterns and construction of a novel prognostic model for prostate cancer based on bulk and single-cell RNA sequencing.
Fu J; Li G; Luo R; Lu Z; Wang Y
Front Endocrinol (Lausanne); 2022; 13():1003594. PubMed ID: 36105400
[TBL] [Abstract][Full Text] [Related]
8. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
9. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
Rui X; Shao S; Wang L; Leng J
BMC Cancer; 2019 Dec; 19(1):1179. PubMed ID: 31795990
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel key genes associated with the metastasis of prostate cancer based on bioinformatics prediction and validation.
Song F; Zhang Y; Pan Z; Hu X; Yi Y; Zheng X; Wei H; Huang P
Cancer Cell Int; 2021 Oct; 21(1):559. PubMed ID: 34696780
[TBL] [Abstract][Full Text] [Related]
11. Development and Verification of a Prostate Cancer Prognostic Signature Based on an Immunogenomic Landscape Analysis.
Cheng H; Wang Y; Liu C; Wu T; Chen S; Chen M
Front Oncol; 2021; 11():711258. PubMed ID: 34568039
[TBL] [Abstract][Full Text] [Related]
12. Identification of a Novel Nomogram to Predict Progression Based on the Circadian Clock and Insights Into the Tumor Immune Microenvironment in Prostate Cancer.
Feng D; Xiong Q; Zhang F; Shi X; Xu H; Wei W; Ai J; Yang L
Front Immunol; 2022; 13():777724. PubMed ID: 35154101
[TBL] [Abstract][Full Text] [Related]
13. Biochemical recurrence related metabolic novel signature associates with immunity and ADT treatment responses in prostate cancer.
Wang X; Lv Z; Xia H; Guo X; Wang J; Wang J; Liu M
Cancer Med; 2023 Jan; 12(1):862-878. PubMed ID: 35681277
[TBL] [Abstract][Full Text] [Related]
14. A Prognostic Model for Prostate Cancer Patients Based on Two DNA Damage Response Mutation-Related Immune Genes.
Wang J; Jiang L; Shang Z; Ye Z; Yuan D; Cui X
Cancer Biother Radiopharm; 2024 May; 39(4):306-317. PubMed ID: 37610864
[No Abstract] [Full Text] [Related]
15. Coexpression Network Analysis Identifies a Novel Nine-RNA Signature to Improve Prognostic Prediction for Prostate Cancer Patients.
Cai J; Chen Z; Chen X; Huang H; Lin X; Miao B
Biomed Res Int; 2020; 2020():4264291. PubMed ID: 32953881
[TBL] [Abstract][Full Text] [Related]
16. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
17. Identification of prognostic immune-related gene signature associated with tumor microenvironment of colorectal cancer.
Wang Y; Li W; Jin X; Jiang X; Guo S; Xu F; Su X; Wang G; Zhao Z; Gu X
BMC Cancer; 2021 Aug; 21(1):905. PubMed ID: 34364366
[TBL] [Abstract][Full Text] [Related]
18. Exploration of the Tumor Mutational Burden as a Prognostic Biomarker and Related Hub Gene Identification in Prostate Cancer.
Wang L; Yao Y; Xu C; Wang X; Wu D; Hong Z
Technol Cancer Res Treat; 2021; 20():15330338211052154. PubMed ID: 34806485
[TBL] [Abstract][Full Text] [Related]
19. Systemic characterization of alternative splicing related to prognosis and immune infiltration in malignant mesothelioma.
Lai J; Yang H; Xu T
BMC Cancer; 2021 Jul; 21(1):848. PubMed ID: 34294080
[TBL] [Abstract][Full Text] [Related]
20. Identification and validation of an individualized metabolic prognostic signature for predicting the biochemical recurrence of prostate cancer based on the immune microenvironment.
Hu B; Zhang X; Zhu S; Wang C; Deng Z; Wang T; Wu Y
Eur J Med Res; 2024 Jan; 29(1):92. PubMed ID: 38297388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
